Next 10 |
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placebo Statistically significant ...
2024-06-14 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Boa...
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company’s newly appointe...
2024-06-07 15:09:58 ET More on Alnylam, Pliant, etc. Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation ...
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including...
2024-05-14 10:04:08 ET More on Pliant Therapeutics Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Pliant Therapeutics Financial information for Pliant Therapeutics Read the full article on Seeking Alpha For fur...
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared ...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including ...
BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring bexotegrast’s effect on total lung collagen and FVC in IPF patients expected in the co...
News, Short Squeeze, Breakout and More Instantly...
Pliant Therapeutics Inc. Company Name:
PLRX Stock Symbol:
NASDAQ Market:
Pliant Therapeutics Inc. Website:
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placebo Statistically significant ...
2024-06-14 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Boa...